```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[S. 2195 Enrolled Bill (ENR)]

        S.2195

                       One Hundred Eighth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

          Begun and held at the City of Washington on Tuesday,
           the twentieth day of January, two thousand and four

                                 An Act

 
  To amend the Controlled Substances Act to clarify the definition of 
 anabolic steroids and to provide for research and education activities 
              relating to steroids and steroid precursors.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Anabolic Steroid Control Act of 
2004''.
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.
    (a) Definitions.--Section 102 of the Controlled Substances Act (21 
U.S.C. 802) is amended--
        (1) in paragraph (41)--
            (A) by realigning the margin so as to align with paragraph 
        (40); and
            (B) by striking subparagraph (A) and inserting the 
        following:
    ``(A) The term `anabolic steroid' means any drug or hormonal 
substance, chemically and pharmacologically related to testosterone 
(other than estrogens, progestins, corticosteroids, and 
dehydroepiandrosterone), and includes--
        ``(i) androstanediol--
            ``(I) 3b,17b-dihydroxy-5a-androstane; and
            ``(II) 3a,17b-dihydroxy-5a-androstane;
        ``(ii) androstanedione (5a-androstan-3,17-dione);
        ``(iii) androstenediol--
            ``(I) 1-androstenediol (3b,17b-dihydroxy-5a-androst-1-ene);
            ``(II) 1-androstenediol (3a,17b-dihydroxy-5a-androst-1-
        ene);
            ``(III) 4-androstenediol (3b,17b-dihydroxy-androst-4-ene); 
        and
            ``(IV) 5-androstenediol (3b,17b-dihydroxy-androst-5-ene);
        ``(iv) androstenedione--
            ``(I) 1-androstenedione ([5a]-androst-1-en-3,17-dione);
            ``(II) 4-androstenedione (androst-4-en-3,17-dione); and
            ``(III) 5-androstenedione (androst-5-en-3,17-dione);
        ``(v) bolasterone (7a,17a-dimethyl-17b-hydroxyandrost-4-en-3-
    one);
        ``(vi) boldenone (17b-hydroxyandrost-1,4,-diene-3-one);
        ``(vii) calusterone (7b,17a-dimethyl-17b-hydroxyandrost-4-en-3-
    one);
        ``(viii) clostebol (4-chloro-17b-hydroxyandrost-4-en-3-one);
        ``(ix) dehydrochloromethyltestosterone (4-chloro-17b-hydroxy-
    17a-methyl-androst-1,4-dien-3-one);
        ``(x) <triangle>1-dihydrotestosterone (a.k.a. `1-testosterone') 
    (17b-hydroxy-5a-androst-1-en-3-one);
        ``(xi) 4-dihydrotestosterone (17b-hydroxy-androstan-3-one);
        ``(xii) drostanolone (17b-hydroxy-2a-methyl-5a-androstan-3-
    one);
        ``(xiii) ethylestrenol (17a-ethyl-17b-hydroxyestr-4-ene);
        ``(xiv) fluoxymesterone (9-fluoro-17a-methyl-11b,17b-
    dihydroxyandrost-4-en-3-one);
        ``(xv) formebolone (2-formyl-17a-methyl-11a,17b-
    dihydroxyandrost-1,4-dien-3-one);
        ``(xvi) furazabol (17a-methyl-17b-hydroxyandrostano[2,3-c]-
    furazan);
        ``(xvii) 13b-ethyl-17a-hydroxygon-4-en-3-one;
        ``(xviii) 4-hydroxytestosterone (4,17b-dihydroxy-androst-4-en-
    3-one);
        ``(xix) 4-hydroxy-19-nortestosterone (4,17b-dihydroxy-estr-4-
    en-3-one);
        ``(xx) mestanolone (17a-methyl-17b-hydroxy-5a-androstan-3-one);
        ``(xxi) mesterolone (1a-methyl-17b-hydroxy-[5a]-androstan-3-
    one);
        ``(xxii) methandienone (17a-methyl-17b-hydroxyandrost-1,4-dien-
    3-one);
        ``(xxiii) methandriol (17a-methyl-3b,17b-dihydroxyandrost-5-
    ene);
        ``(xxiv) methenolone (1-methyl-17b-hydroxy-5a-androst-1-en-3-
    one);
        ``(xxv) 17a-methyl-3b, 17b-dihydroxy-5a-androstane;
        ``(xxvi) 17a-methyl-3a,17b-dihydroxy-5a-androstane;
        ``(xxvii) 17a-methyl-3b,17b-dihydroxyandrost-4-ene.
        ``(xxviii) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-
    hydroxy-17b-hydroxyestr-4-en-3-one);
        ``(xxix) methyldienolone (17a-methyl-17b-hydroxyestra-4,9(10)-
    dien-3-one);
        ``(xxx) methyltrienolone (17a-methyl-17b-hydroxyestra-4,9-11-
    trien-3-one);
        ``(xxxi) methyltestosterone (17a-methyl-17b-hydroxyandrost-4-
    en-3-one);
        ``(xxxii) mibolerone (7a,17a-dimethyl-17b-hydroxyestr-4-en-3-
    one);
        ``(xxxiii) 17a-methyl-<triangle>1-dihydrotestosterone (17b-
    hydroxy-17a-methyl-5a-androst-1-en-3-one) (a.k.a. `17-a-methyl-1-
    testosterone');
        ``(xxxiv) nandrolone (17b-hydroxyestr-4-en-3-one);
        ``(xxxv) norandrostenediol--
            ``(I) 19-nor-4-androstenediol (3b, 17b-dihydroxyestr-4-
        ene);
            ``(II) 19-nor-4-androstenediol (3a, 17b-dihydroxyestr-4-
        ene);
            ``(III) 19-nor-5-androstenediol (3b, 17b-dihydroxyestr-5-
        ene); and
            ``(IV) 19-nor-5-androstenediol (3a, 17b-dihydroxyestr-5-
        ene);
        ``(xxxvi) norandrostenedione--
            ``(I) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and
            ``(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
        ``(xxxvii) norbolethone (13b,17a-diethyl-17b-hydroxygon-4-en-3-
    one);
        ``(xxxviii) norclostebol (4-chloro-17b-hydroxyestr-4-en-3-one);
        ``(xxxix) norethandrolone (17a-ethyl-17b-hydroxyestr-4-en-3-
    one);
        ``(xl) normethandrolone (17a-methyl-17b-hydroxyestr-4-en-3-
    one);
        ``(xli) oxandrolone (17a-methyl-17b-hydroxy-2-oxa-[5a]-
    androstan-3-one);
        ``(xlii) oxymesterone (17a-methyl-4,17b-dihydroxyandrost-4-en-
    3-one);
        ``(xliii) oxymetholone (17a-methyl-2-hydroxymethylene-17b-
    hydroxy-[5a]-androstan-3-one);
        ``(xliv) stanozolol (17a-methyl-17a-hydroxy-[5a]-androst-2-
    eno[3,2-c]-pyrazole);
        ``(xlv) stenbolone (17b-hydroxy-2-methyl-[5a]-androst-1-en-3-
    one);
        ``(xlvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-
    dien-17-oic acid lactone);
        ``(xlvii) testosterone (17b-hydroxyandrost-4-en-3-one);
        ``(xlviii) tetrahydrogestrinone (13b,17a-diethyl-17b-
    hydroxygon-4,9,11-trien-3-one);
        ``(xlix) trenbolone (17b-hydroxyestr-4,9,11-trien-3-one); and
        ``(xlx) any salt, ester, or ether of a drug or substance 
    described in this paragraph.
The substances excluded under this subparagraph may at any time be 
scheduled by the Attorney General in accordance with the authority and 
requirements of subsections (a) through (c) of section 201.''; and
        (2) in paragraph (44), by inserting ``anabolic steroids,'' 
    after ``marihuana,''.
    (b) Authority and Criteria for Classification.--Section 201(g) of 
the Controlled Substances Act (21 U.S.C. 811(g)) is amended--
        (1) in paragraph (1), by striking ``substance from a schedule 
    if such substance'' and inserting ``drug which contains a 
    controlled substance from the application of titles II and III of 
    the Comprehensive Drug Abuse Prevention and Control Act (21 U.S.C. 
    802 et seq.) if such drug''; and
        (2) in paragraph (3), by adding at the end the following:
        ``(C) Upon the recommendation of the Secretary of Health and 
    Human Services, a compound, mixture, or preparation which contains 
    any anabolic steroid, which is intended for administration to a 
    human being or an animal, and which, because of its concentration, 
    preparation, formulation or delivery system, does not present any 
    significant potential for abuse.''.
    (c) Anabolic Steroids Control Act.--Section 1903 of the Anabolic 
Steroids Control Act of 1990 (Public Law 101-647) is amended--
        (1) by striking subsection (a); and
        (2) by redesignating subsections (b) and (c) as subsections (a) 
    and (b), respectively.
    (d) Effective Date.--The amendments made by this section shall take 
effect 90 days after the date of enactment of this Act.

SEC. 3. SENTENCING COMMISSION GUIDELINES.

    The United States Sentencing Commission shall--
        (1) review the Federal sentencing guidelines with respect to 
    offenses involving anabolic steroids;
        (2) consider amending the Federal sentencing guidelines to 
    provide for increased penalties with respect to offenses involving 
    anabolic steroids in a manner that reflects the seriousness of such 
    offenses and the need to deter anabolic steroid trafficking and 
    use; and
        (3) take such other action that the Commission considers 
    necessary to carry out this section.

SEC. 4. PREVENTION AND EDUCATION PROGRAMS.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this Act as the ``Secretary'') shall award grants to 
public and nonprofit private entities to enable such entities to carry 
out science-based education programs in elementary and secondary 
schools to highlight the harmful effects of anabolic steroids.
    (b) Eligibility.--
        (1) Application.--To be eligible for grants under subsection 
    (a), an entity shall prepare and submit to the Secretary an 
    application at such time, in such manner, and containing such 
    information as the Secretary may require.
        (2) Preference.--In awarding grants under subsection (a), the 
    Secretary shall give preference to applicants that intend to use 
    grant funds to carry out programs based on--
            (A) the Athletes Training and Learning to Avoid Steroids 
        program;
            (B) The Athletes Targeting Healthy Exercise and Nutrition 
        Alternatives program; and
            (C) other programs determined to be effective by the 
        National Institute on Drug Abuse.
    (c) Use of Funds.--Amounts received under a grant under subsection 
(a) shall be used for education programs that will directly communicate 
with teachers, principals, coaches, as well as elementary and secondary 
school children concerning the harmful effects of anabolic steroids.
    (d) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section, $15,000,000 for each of fiscal 
years 2005 through 2010.
SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.
    (a) In General.--The Secretary of Health and Human Services shall 
ensure that the National Survey on Drug Use and Health includes 
questions concerning the use of anabolic steroids.
    (b) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section, $1,000,000 for each of fiscal 
years 2005 through 2010.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```